HPV Vaccine Now Approved For Men And Women Aged 27 To 45, FDA Says.
The New York Times (10/5) reported that “the HPV vaccine…is now approved for men and women from 27 to 45-years-old, the Food and Drug Administration said” yesterday.
CNN (10/5) reports that the agency “said it based the expansion on results of a study of 3,200 women followed over 3½ years.” The research “found that Gardasil 9 was 88% effective in the prevention of vulvar, vaginal and cervical precancerous lesions, cervical cancer and genital warts caused by the nine HPV strains.” CNN adds, “The effectiveness of the vaccine in men was ‘inferred’ from the data on women as well as a clinical trial of 150 men ages 27 to 45 who received a three-dose vaccination regimen over a six-month period.”
The Washington Post (10/5) reported, “The approval ‘represents an important opportunity to help prevent HPV-related diseases and cancers in a broader age range,’ said Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research.”
Brought to you by: The Morning Brief
The Morning Brief is a digest of the most important news selected from thousands of sources by the editors of BulletinHealthcare and delivered digitally to members of the American Osteopathic Association (AOA). This is provided to members solely as information that may be of interest. The AOA does not endorse these articles, nor views expressed therein. Neither the AOA nor BulletinHealthcare is responsible for the accuracy of the content. Similarly, the presence of advertising neither constitutes nor implies endorsement of any of the advertised products or services by the AOA.
Other News Sources: